LYBALVI FDA approval date

The FDA approved LYBALVI on 28 May 2021.

FDA approval date
28 May 2021

Drug identity has not yet been verified against registry records

Also recorded as OLANZAPINE; SAMIDORPHAN L-MALATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2021-05-28DayLYBALVIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA213378", "applicant_as_listed_by_fda": "ALKERMES INC", "brand_names": ["LYBALVI"], "active_ingredients": ["OLANZAPINE", "SAMIDORPHAN L-MALATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210528", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026